Neoleukin Therapeutics Key Executives
This section highlights Neoleukin Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Neoleukin Therapeutics
(Showing 0 of )
Neoleukin Therapeutics Earnings
This section highlights Neoleukin Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
$3.49
Stock Price
$8.20M
Market Cap
107
Employees
Seattle, WA
Location
Financial Statements
Access annual & quarterly financial statements for Neoleukin Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $- | $6.00K | $451.00K | $- | $25.00M |
| Cost of Revenue | $- | $- | $- | $- | $- |
| Gross Profit | $- | $6.00K | $451.00K | $- | $25.00M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% |
| Research and Development Expenses | $41.13M | $39.16M | $24.34M | $4.42M | $41.79M |
| General and Administrative Expenses | $17.97M | $21.54M | $17.21M | $18.83M | $15.84M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $17.97M | $21.54M | $17.21M | $18.83M | $15.84M |
| Other Expenses | $-42.00K | $6.00K | $-44.00K | $-8.00K | $-445.00K |
| Operating Expenses | $59.10M | $60.70M | $41.55M | $23.24M | $57.62M |
| Cost and Expenses | $59.10M | $60.70M | $41.55M | $23.24M | $57.62M |
| Interest Income | $1.58M | $19.00K | $490.00K | $1.54M | $1.56M |
| Interest Expense | $1.58M | $- | $- | $1.00K | $4.00K |
| Depreciation and Amortization | $2.61M | $2.28M | $-13.84M | $49.59M | $1.04M |
| EBITDA | $-56.48M | $-60.70M | $-47.56M | $-21.37M | $-31.51M |
| EBITDA Ratio | 0.00% | -1011633.33% | -10546.34% | 0.00% | -126.02% |
| Operating Income | $-59.10M | $-60.70M | $-33.73M | $-70.96M | $-32.62M |
| Operating Income Ratio | 0.00% | -1011633.33% | -7478.49% | 0.00% | -130.50% |
| Total Other Income Expenses Net | $1.54M | $6.00K | $7.83M | $1.52M | $1.04M |
| Income Before Tax | $-57.56M | $-60.69M | $-33.28M | $-69.44M | $-31.59M |
| Income Before Tax Ratio | 0.00% | -1011533.33% | -7378.49% | 0.00% | -126.34% |
| Income Tax Expense | $-1.54M | $-2.28M | $-8.32M | $-7.00K | $-1.04M |
| Net Income | $-56.02M | $-58.41M | $-24.96M | $-69.44M | $-31.59M |
| Net Income Ratio | 0.00% | -973583.33% | -5533.48% | 0.00% | -126.34% |
| EPS | $-1.01 | $-1.06 | $-0.48 | $-2.57 | $-1.34 |
| EPS Diluted | $-1.01 | $-1.06 | $-0.48 | $-2.57 | $-1.34 |
| Weighted Average Shares Outstanding | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M |
| Weighted Average Shares Outstanding Diluted | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $6.00K | $6.00K | $- | $- | $451.00K | $1.00K | $- | $- | $- | $- | $- | $- | $-25.00M |
| Cost of Revenue | $- | $- | $3.42M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-3.42M | $- | $- | $- | $- | $6.00K | $6.00K | $- | $- | $451.00K | $1.00K | $- | $- | $- | $- | $- | $- | $-25.00M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research and Development Expenses | $617.00K | $-426.00K | $7.69M | $10.00M | $9.47M | $10.96M | $10.70M | $9.76M | $9.90M | $9.82M | $9.71M | $7.79M | $6.22M | $4.84M | $5.50M | $4.89M | $1.42M | $-2.00M | $104.00K | $2.57M |
| General and Administrative Expenses | $4.95M | $3.49M | $4.03M | $4.25M | $4.14M | $4.92M | $4.66M | $5.41M | $5.56M | $5.30M | $5.24M | $4.85M | $3.86M | $4.93M | $3.57M | $3.47M | $10.38M | $2.42M | $2.56M | $2.73M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.95M | $3.49M | $4.03M | $4.25M | $4.14M | $4.92M | $4.66M | $5.41M | $5.56M | $5.30M | $5.24M | $4.85M | $3.86M | $4.93M | $3.57M | $3.47M | $10.38M | $2.42M | $2.56M | $2.73M |
| Other Expenses | $- | $- | $-14.00K | $-2.00K | $-23.00K | $-16.00K | $- | $- | $- | $-11.00K | $- | $-1.00K | $-4.00K | $-19.00K | $-20.00K | $2.00K | $-9.00K | $- | $-1.00K | $-12.00K |
| Operating Expenses | $5.57M | $3.07M | $11.72M | $14.25M | $13.61M | $15.87M | $15.37M | $15.17M | $15.45M | $15.12M | $14.95M | $12.64M | $10.08M | $9.77M | $9.07M | $8.36M | $11.80M | $428.00K | $2.66M | $5.30M |
| Cost and Expenses | $5.57M | $3.07M | $11.72M | $14.25M | $13.61M | $15.87M | $15.37M | $15.17M | $15.45M | $15.12M | $14.95M | $12.64M | $10.08M | $9.77M | $9.07M | $8.36M | $11.80M | $428.00K | $2.66M | $5.30M |
| Interest Income | $1.04M | $981.00K | $945.00K | $816.00K | $559.00K | $194.00K | $13.00K | $5.00K | $6.00K | $5.00K | $3.00K | $3.00K | $7.00K | $47.00K | $434.00K | $264.00K | $392.00K | $436.00K | $450.00K | $470.00K |
| Interest Expense | $- | $- | $- | $816.00K | $559.00K | $194.00K | $13.00K | $5.00K | $6.00K | $5.00K | $3.00K | $3.00K | $7.00K | $47.00K | $434.00K | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $381.00K | $371.00K | $7.45M | $643.00K | $589.00K | $713.00K | $661.00K | $631.00K | $592.00K | $542.00K | $512.00K | $459.00K | $441.00K | $222.00K | $699.00K | $255.00K | $384.00K | $427.00K | $451.00K | $413.00K |
| EBITDA | $-5.19M | $-2.69M | $-7.68M | $-13.61M | $-13.02M | $-15.16M | $-14.71M | $-14.54M | $-14.86M | $-14.58M | $-14.43M | $-12.18M | $-17.46M | $-9.54M | $-8.39M | $-54.54M | $35.91M | $-419.00K | $-2.66M | $-4.22M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -242416.67% | -247666.67% | 0.00% | 0.00% | -2699.56% | -1745900.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.86% |
| Operating Income | $-5.57M | $-3.07M | $-15.13M | $-14.25M | $-13.61M | $-15.87M | $-15.37M | $-15.17M | $-15.45M | $-15.13M | $-14.95M | $-54.82M | $2.25M | $-9.75M | $-8.64M | $-8.36M | $-59.52M | $-428.00K | $-2.66M | $-5.30M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -252783.33% | -257433.33% | 0.00% | 0.00% | -12154.77% | 225000.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 21.20% |
| Total Other Income Expenses Net | $1.04M | $981.00K | $931.00K | $834.00K | $537.00K | $183.00K | $15.00K | $1.00K | $- | $- | $- | $-28.78M | $7.83M | $- | $444.00K | $255.00K | $384.00K | $427.00K | $451.00K | $413.00K |
| Income Before Tax | $-4.53M | $-2.08M | $-14.20M | $-13.45M | $-13.07M | $-15.69M | $-15.35M | $-15.17M | $-15.45M | $-15.13M | $-14.95M | $-12.64M | $-2.25M | $-9.75M | $-8.64M | $-8.10M | $-59.13M | $-1.00K | $-2.21M | $-4.89M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -252783.33% | -257433.33% | 0.00% | 0.00% | -2802.66% | -224900.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.55% |
| Income Tax Expense | $- | $- | $5.91M | $-806.00K | $-537.00K | $-382.00K | $13.00K | $-5.00K | $-6.00K | $-5.00K | $-3.00K | $-3.00K | $-7.00K | $-47.00K | $-434.00K | $-255.00K | $-384.00K | $-427.00K | $-451.00K | $-413.00K |
| Net Income | $-4.53M | $-2.08M | $-20.11M | $-12.64M | $-12.54M | $-15.31M | $-15.36M | $-15.17M | $-15.45M | $-15.13M | $-14.95M | $-12.64M | $-2.25M | $-9.75M | $-8.64M | $-8.10M | $-59.13M | $-1.00K | $-2.21M | $-4.89M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -252783.33% | -257433.33% | 0.00% | 0.00% | -2802.66% | -224900.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 19.55% |
| EPS | $-0.41 | $-0.19 | $-1.81 | $-0.23 | $-1.13 | $-0.28 | $-0.28 | $-0.28 | $-0.28 | $-0.27 | $-0.27 | $-0.23 | $-0.04 | $-0.20 | $-0.18 | $-0.16 | $-2.26 | $0.00 | $-0.09 | $-0.21 |
| EPS Diluted | $-0.41 | $-0.19 | $-1.81 | $-0.23 | $-1.13 | $-0.28 | $-0.28 | $-0.28 | $-0.28 | $-0.27 | $-0.27 | $-0.23 | $-0.04 | $-0.20 | $-0.18 | $-0.16 | $-2.26 | $0.00 | $-0.09 | $-0.21 |
| Weighted Average Shares Outstanding | 11.10M | 11.23M | 11.08M | 11.06M | 11.05M | 11.04M | 11.03M | 11.02M | 11.02M | 11.01M | 10.99M | 10.37M | 10.82M | 9.88M | 9.83M | 5.41M | 5.24M | 4.71M | 4.71M | 4.71M |
| Weighted Average Shares Outstanding Diluted | 11.10M | 11.23M | 11.08M | 11.06M | 11.05M | 11.04M | 11.03M | 11.02M | 11.02M | 11.01M | 10.99M | 10.37M | 10.82M | 9.88M | 9.83M | 5.41M | 5.24M | 4.71M | 4.71M | 4.71M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $37.89M | $142.47M | $192.56M | $143.09M | $76.93M |
| Short Term Investments | $58.50M | $- | $- | $- | $- |
| Cash and Short Term Investments | $96.38M | $142.47M | $192.56M | $143.09M | $76.93M |
| Net Receivables | $- | $- | $- | $503.00K | $237.00K |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $2.75M | $1.52M | $1.97M | $- | $- |
| Total Current Assets | $99.13M | $143.99M | $194.52M | $143.60M | $77.17M |
| Property Plant Equipment Net | $15.88M | $17.22M | $13.72M | $2.83M | $400.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $128.00K | $347.00K | $567.00K | $- |
| Goodwill and Intangible Assets | $- | $128.00K | $347.00K | $567.00K | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $936.00K | $1.93M | $1.93M | $30.00K | $53.00K |
| Total Non-Current Assets | $16.81M | $19.27M | $16.00M | $3.43M | $453.00K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $115.95M | $163.26M | $210.52M | $147.02M | $77.62M |
| Account Payables | $478.00K | $526.00K | $1.32M | $1.60M | $702.00K |
| Short Term Debt | $1.51M | $1.22M | $708.00K | $618.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $9.07M | $6.89M | $5.86M | $2.52M | $3.92M |
| Total Current Liabilities | $11.06M | $8.64M | $7.89M | $4.74M | $4.63M |
| Long Term Debt | $10.55M | $11.76M | $11.41M | $593.00K | $6.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $313.00K |
| Total Non-Current Liabilities | $10.55M | $11.76M | $11.41M | $593.00K | $319.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $21.62M | $20.40M | $19.30M | $5.34M | $4.95M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $- | $- | $- |
| Retained Earnings | $-451.06M | $-393.50M | $-332.81M | $-299.53M | $-230.09M |
| Accumulated Other Comprehensive Income Loss | $-21.00K | $- | $- | $- | $-443.00K |
| Other Total Stockholders Equity | $545.41M | $536.36M | $524.02M | $441.22M | $303.20M |
| Total Stockholders Equity | $94.33M | $142.86M | $191.22M | $141.69M | $72.67M |
| Total Equity | $94.33M | $142.86M | $191.22M | $141.69M | $72.67M |
| Total Liabilities and Stockholders Equity | $115.95M | $163.26M | $210.52M | $147.02M | $77.62M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $115.95M | $163.26M | $210.52M | $147.02M | $77.62M |
| Total Investments | $58.50M | $- | $- | $- | $- |
| Total Debt | $12.07M | $12.98M | $12.12M | $1.21M | $6.00K |
| Net Debt | $-25.82M | $-129.48M | $-180.43M | $-141.88M | $-76.92M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $25.23M | $31.11M | $35.49M | $37.89M | $40.34M | $77.53M | $128.06M | $142.47M | $154.92M | $164.24M | $178.39M | $192.56M | $201.15M | $129.60M | $139.42M | $143.09M | $66.31M | $72.70M | $74.17M | $76.93M |
| Short Term Investments | $53.28M | $50.95M | $47.94M | $58.50M | $66.54M | $38.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $78.51M | $82.06M | $83.44M | $96.38M | $106.88M | $116.46M | $128.06M | $142.47M | $154.92M | $164.24M | $178.39M | $192.56M | $201.15M | $129.60M | $139.42M | $143.09M | $66.31M | $72.70M | $74.17M | $76.93M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $236.00K | $503.00K | $1.28M | $509.00K | $662.00K | $237.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $1.39M | $1.72M | $2.20M | $2.75M | $1.98M | $2.03M | $2.31M | $1.52M | $1.57M | $3.26M | $2.92M | $1.97M | $5.44M | $1.40M | $- | $- | $- | $- | $- | $- |
| Total Current Assets | $79.89M | $83.78M | $85.64M | $99.13M | $108.86M | $118.48M | $130.37M | $143.99M | $156.50M | $167.50M | $181.31M | $194.52M | $206.59M | $131.00M | $139.65M | $143.60M | $67.58M | $73.21M | $74.83M | $77.17M |
| Property Plant Equipment Net | $9.17M | $9.70M | $11.92M | $15.88M | $15.81M | $16.50M | $16.74M | $17.22M | $17.27M | $17.36M | $16.58M | $13.72M | $13.70M | $12.74M | $12.35M | $2.83M | $1.56M | $504.00K | $570.00K | $400.00K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $18.00K | $73.00K | $128.00K | $183.00K | $238.00K | $293.00K | $347.00K | $403.00K | $458.00K | $513.00K | $567.00K | $622.00K | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $18.00K | $73.00K | $128.00K | $183.00K | $238.00K | $293.00K | $347.00K | $403.00K | $458.00K | $513.00K | $567.00K | $622.00K | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $524.00K | $529.00K | $905.00K | $936.00K | $1.91M | $2.02M | $1.95M | $1.93M | $1.99M | $1.93M | $1.92M | $1.93M | $997.00K | $1.13M | $535.00K | $30.00K | $29.00K | $30.00K | $33.00K | $53.00K |
| Total Non-Current Assets | $9.69M | $10.22M | $12.82M | $16.81M | $17.72M | $18.54M | $18.76M | $19.27M | $19.44M | $19.53M | $18.80M | $16.00M | $15.10M | $14.33M | $13.40M | $3.43M | $2.21M | $534.00K | $603.00K | $453.00K |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $89.59M | $94.00M | $98.46M | $115.95M | $126.58M | $137.02M | $149.13M | $163.26M | $175.93M | $187.02M | $200.10M | $210.52M | $221.69M | $145.32M | $153.05M | $147.02M | $69.79M | $73.74M | $75.43M | $77.62M |
| Account Payables | $- | $- | $- | $478.00K | $8.86M | $7.89M | $6.33M | $526.00K | $7.77M | $6.41M | $7.31M | $1.32M | $9.52M | $6.01M | $5.00M | $1.60M | $2.30M | $958.00K | $3.40M | $702.00K |
| Short Term Debt | $1.55M | $1.49M | $1.74M | $1.51M | $1.38M | $1.39M | $1.27M | $1.22M | $1.22M | $1.18M | $1.10M | $708.00K | $370.00K | $306.00K | $600.00K | $618.00K | $265.00K | $201.00K | $200.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $-8.86M | $-7.89M | $-6.33M | $- | $-7.77M | $-6.41M | $-7.31M | $-696.69K | $-9.52M | $-6.01M | $-5.00M | $- | $-2.30M | $-958.00K | $-3.40M | $- |
| Other Current Liabilities | $3.66M | $3.39M | $5.42M | $9.07M | $8.86M | $7.89M | $6.33M | $6.89M | $7.77M | $6.41M | $7.31M | $6.55M | $9.52M | $6.01M | $5.00M | $2.52M | $2.30M | $958.00K | $3.40M | $3.92M |
| Total Current Liabilities | $5.21M | $4.88M | $7.16M | $11.06M | $10.24M | $9.27M | $7.60M | $8.64M | $9.00M | $7.58M | $8.41M | $7.89M | $9.89M | $6.32M | $5.60M | $4.74M | $2.56M | $1.16M | $3.60M | $4.63M |
| Long Term Debt | $9.14M | $9.55M | $9.95M | $10.55M | $10.69M | $11.04M | $11.44M | $11.76M | $12.07M | $12.37M | $12.73M | $11.41M | $11.46M | $10.30M | $10.33M | $593.00K | $351.00K | $255.00K | $296.00K | $6.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $313.00K |
| Total Non-Current Liabilities | $9.14M | $9.55M | $9.95M | $10.55M | $10.69M | $11.04M | $11.44M | $11.76M | $12.07M | $12.37M | $12.73M | $11.41M | $11.46M | $10.30M | $10.33M | $593.00K | $351.00K | $255.00K | $296.00K | $319.00K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $14.35M | $14.43M | $17.10M | $21.62M | $20.93M | $20.31M | $19.03M | $20.40M | $21.07M | $19.95M | $21.14M | $19.30M | $21.35M | $16.62M | $15.93M | $5.34M | $2.92M | $1.41M | $3.89M | $4.95M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Retained Earnings | $-471.87M | $-467.34M | $-465.26M | $-451.06M | $-437.61M | $-424.54M | $-408.85M | $-393.50M | $-378.33M | $-362.88M | $-347.76M | $-332.81M | $-320.17M | $-317.92M | $-308.17M | $-299.53M | $-291.43M | $-232.30M | $-232.29M | $-230.09M |
| Accumulated Other Comprehensive Income Loss | $- | $-13.00K | $18.00K | $-21.00K | $-92.00K | $-72.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-688.00K | $- | $- | $- | $-443.00K |
| Other Total Stockholders Equity | $547.11M | $546.93M | $546.60M | $545.41M | $543.35M | $541.32M | $538.94M | $536.36M | $533.20M | $529.96M | $526.72M | $524.02M | $520.51M | $446.62M | $445.29M | $441.90M | $358.30M | $304.62M | $303.84M | $303.20M |
| Total Stockholders Equity | $75.23M | $79.58M | $81.36M | $94.33M | $105.65M | $116.71M | $130.09M | $142.86M | $154.87M | $167.07M | $178.97M | $191.22M | $200.34M | $128.70M | $137.12M | $141.69M | $66.88M | $72.33M | $71.54M | $72.67M |
| Total Equity | $75.23M | $79.58M | $81.36M | $94.33M | $105.65M | $116.71M | $130.09M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $89.59M | $94.00M | $98.46M | $115.95M | $126.58M | $137.02M | $149.13M | $163.26M | $175.93M | $187.02M | $200.10M | $210.52M | $221.69M | $145.32M | $153.05M | $147.02M | $69.79M | $73.74M | $75.43M | $77.62M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $89.59M | $94.00M | $98.46M | $115.95M | $126.58M | $137.02M | $149.13M | $163.26M | $175.93M | $187.02M | $200.10M | $210.52M | $221.69M | $145.32M | $153.05M | $147.02M | $69.79M | $73.74M | $75.43M | $77.62M |
| Total Investments | $53.28M | $50.95M | $47.94M | $58.50M | $66.54M | $38.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $10.69M | $11.04M | $11.68M | $12.07M | $12.07M | $12.43M | $12.71M | $12.98M | $13.29M | $13.54M | $13.83M | $12.12M | $11.83M | $10.61M | $10.93M | $1.21M | $616.00K | $456.00K | $496.00K | $6.00K |
| Net Debt | $-14.53M | $-20.07M | $-23.81M | $-25.82M | $-28.26M | $-65.10M | $-115.35M | $-129.48M | $-141.63M | $-150.69M | $-164.56M | $-180.43M | $-189.32M | $-118.98M | $-128.49M | $-141.88M | $-65.69M | $-72.24M | $-73.67M | $-76.92M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-57.56M | $-60.69M | $-33.28M | $-69.44M | $-31.59M |
| Depreciation and Amortization | $2.61M | $2.28M | $1.82M | $340.00K | $- |
| Deferred Income Tax | $- | $- | $- | $263.00K | $- |
| Stock Based Compensation | $8.83M | $11.56M | $5.62M | $7.68M | $4.70M |
| Change in Working Capital | $885.00K | $-700.00K | $966.00K | $-1.95M | $-5.43M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $2.26M | $-142.00K | $3.02M | $-2.24M | $-6.47M |
| Other Working Capital | $-1.37M | $-558.00K | $-2.05M | $290.00K | $1.04M |
| Other Non Cash Items | $-376.00K | $- | $293.00K | $47.72M | $741.00K |
| Net Cash Provided by Operating Activities | $-45.61M | $-47.56M | $-24.57M | $-15.39M | $-31.58M |
| Investments in Property Plant and Equipment | $-1.11M | $-3.26M | $-2.22M | $-879.00K | $-49.00K |
| Acquisitions Net | $- | $- | $- | $191.00K | $- |
| Purchases of Investments | $-107.52M | $- | $- | $- | $- |
| Sales Maturities of Investments | $49.50M | $- | $- | $- | $56.00M |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-59.13M | $-3.26M | $-2.22M | $-688.00K | $55.95M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $134.00K | $- | $71.67M | $86.22M | $- |
| Common Stock Repurchased | $82.00K | $372.00K | $199.00K | $560.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $161.00K | $732.00K | $77.14M | $82.24M | $570.00K |
| Net Cash Used Provided by Financing Activities | $161.00K | $732.00K | $77.14M | $82.24M | $570.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $10.00K | $-48.00K |
| Net Change in Cash | $-104.58M | $-50.09M | $50.34M | $66.17M | $24.90M |
| Cash at End of Period | $38.77M | $143.34M | $193.43M | $143.09M | $76.93M |
| Cash at Beginning of Period | $143.34M | $193.43M | $143.09M | $76.93M | $52.03M |
| Operating Cash Flow | $-45.61M | $-47.56M | $-24.57M | $-15.39M | $-31.58M |
| Capital Expenditure | $-1.11M | $-3.26M | $-2.22M | $-879.00K | $-49.00K |
| Free Cash Flow | $-46.72M | $-50.82M | $-26.79M | $-16.27M | $-31.63M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-4.53M | $-2.08M | $-14.20M | $-13.45M | $-13.07M | $-15.69M | $-15.35M | $-15.17M | $-15.45M | $-15.13M | $-14.95M | $-12.64M | $-2.25M | $-9.75M | $-8.64M | $-8.10M | $-59.13M | $-1.00K | $-2.21M | $-4.89M |
| Depreciation and Amortization | $381.00K | $371.00K | $615.00K | $643.00K | $590.00K | $718.00K | $661.00K | $631.00K | $592.00K | $542.00K | $512.00K | $459.00K | $441.00K | $222.00K | $699.00K | $340.00K | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $700.00K | $- | $- | $- | $-966.00K | $- | $- | $- | $-340.00K | $- | $- | $- | $- |
| Stock Based Compensation | $172.00K | $331.00K | $1.19M | $2.04M | $2.03M | $2.31M | $2.45M | $3.01M | $3.21M | $2.92M | $2.42M | $2.23M | $1.69M | $1.02M | $683.00K | $666.00K | $5.15M | $788.00K | $1.08M | $837.00K |
| Change in Working Capital | $260.00K | $-1.78M | $-3.71M | $208.00K | $1.16M | $1.36M | $-1.85M | $-641.00K | $2.89M | $-1.61M | $-1.34M | $723.00K | $-20.00K | $-571.00K | $834.00K | $2.47M | $-388.00K | $-2.34M | $-1.70M | $-5.84M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $-3.94M | $2.26M | $- | $- | $-769.00K | $-142.00K | $- | $- | $-631.00K | $2.45M | $- | $- | $568.00K | $1.73M | $-181.00K | $-2.50M | $-1.30M | $-6.16M |
| Other Working Capital | $- | $- | $226.00K | $-2.05M | $- | $- | $-1.08M | $-499.00K | $- | $- | $-709.00K | $-1.73M | $-20.00K | $-571.00K | $266.00K | $743.00K | $-207.00K | $157.00K | $-403.00K | $321.00K |
| Other Non Cash Items | $-556.00K | $-884.00K | $3.08M | $-379.00K | $- | $3.00K | $- | $-700.00K | $- | $- | $- | $966.00K | $28.00K | $279.00K | $-14.00K | $327.00K | $47.84M | $81.00K | $74.00K | $113.00K |
| Net Cash Provided by Operating Activities | $-4.27M | $-4.05M | $-13.03M | $-10.93M | $-9.29M | $-11.29M | $-14.09M | $-12.17M | $-8.76M | $-13.28M | $-13.36M | $-9.23M | $-112.00K | $-8.79M | $-6.44M | $-4.64M | $-6.53M | $-1.47M | $-2.76M | $-9.78M |
| Investments in Property Plant and Equipment | $- | $-132.00K | $-419.00K | $-104.00K | $-322.00K | $-232.00K | $-452.00K | $-396.00K | $-587.00K | $-1.19M | $-1.09M | $-653.00K | $-487.00K | $-972.00K | $-107.00K | $-782.00K | $-97.00K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $-39.07M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $191.00K | $- | $- | $- | $- |
| Purchases of Investments | $-36.61M | $-26.89M | $-28.38M | $-25.93M | $-42.53M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $35.00M | $24.50M | $39.50M | $34.50M | $15.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $2.12M | $- | $39.07M | $- | $-39.07M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-191.00K | $191.00K | $- | $- | $- |
| Net Cash Used for Investing Activities | $-1.61M | $-411.00K | $10.71M | $8.47M | $-27.85M | $-39.30M | $-452.00K | $-396.00K | $-587.00K | $-1.19M | $-1.09M | $-653.00K | $-487.00K | $-972.00K | $-107.00K | $-782.00K | $94.00K | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $134.00K | $- | $- | $- | $411.00K | $- | $- | $- | $71.67M | $- | $- | $- | $1.55M | $15.05M | $- | $- | $602.00K |
| Common Stock Repurchased | $- | $- | $- | $82.00K | $- | $- | $- | $372.00K | $- | $- | $- | $199.00K | $- | $- | $- | $560.00K | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $-783.00K | $- | $- | $- | $- | $- | $- | $- | $-2.12M | $- | $- | $- | $- |
| Other Financing Activities | $-1.00K | $-294.00K | $-66.00K | $18.00K | $-52.00K | $62.00K | $133.00K | $890.00K | $32.00K | $311.00K | $282.00K | $1.29M | $72.16M | $301.00K | $3.39M | $84.32M | $-15.02M | $-2.00K | $-2.00K | $-2.00K |
| Net Cash Used Provided by Financing Activities | $-1.00K | $-294.00K | $-66.00K | $18.00K | $-52.00K | $62.00K | $133.00K | $107.00K | $32.00K | $311.00K | $282.00K | $1.29M | $72.16M | $301.00K | $3.39M | $82.20M | $37.00K | $-2.00K | $-2.00K | $-2.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.00K | $14.00K | $-11.00K | $1.00K | $7.00K | $3.00K | $-1.00K | $-26.00K |
| Net Change in Cash | $-5.88M | $-4.75M | $-2.39M | $-2.45M | $-37.19M | $-50.53M | $-14.41M | $-12.46M | $-9.31M | $-14.16M | $-14.16M | $-8.59M | $71.55M | $-9.45M | $-3.17M | $76.79M | $-6.39M | $-1.47M | $-2.76M | $-9.80M |
| Cash at End of Period | $25.73M | $31.62M | $36.37M | $38.77M | $41.21M | $78.40M | $128.94M | $143.34M | $155.80M | $165.11M | $179.27M | $193.43M | $202.03M | $130.47M | $139.93M | $143.09M | $66.31M | $72.70M | $74.17M | $76.93M |
| Cash at Beginning of Period | $31.62M | $36.37M | $38.77M | $41.21M | $78.40M | $128.94M | $143.34M | $155.80M | $165.11M | $179.27M | $193.43M | $202.03M | $130.47M | $139.93M | $143.09M | $66.31M | $72.70M | $74.17M | $76.93M | $86.73M |
| Operating Cash Flow | $-4.27M | $-4.05M | $-13.03M | $-10.93M | $-9.29M | $-11.29M | $-14.09M | $-12.17M | $-8.76M | $-13.28M | $-13.36M | $-9.23M | $-112.00K | $-8.79M | $-6.44M | $-4.64M | $-6.53M | $-1.47M | $-2.76M | $-9.78M |
| Capital Expenditure | $- | $-132.00K | $-419.00K | $-104.00K | $-322.00K | $-232.00K | $-452.00K | $-396.00K | $-587.00K | $-1.19M | $-1.09M | $-653.00K | $-487.00K | $-972.00K | $-107.00K | $-782.00K | $-97.00K | $- | $- | $- |
| Free Cash Flow | $-4.27M | $-4.18M | $-13.45M | $-11.04M | $-9.61M | $-11.53M | $-14.54M | $-12.56M | $-9.34M | $-14.47M | $-14.45M | $-9.88M | $-599.00K | $-9.77M | $-6.55M | $-5.42M | $-6.63M | $-1.47M | $-2.76M | $-9.78M |
Neoleukin Therapeutics Dividends
Explore Neoleukin Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Neoleukin Therapeutics News
Read the latest news about Neoleukin Therapeutics, including recent articles, headlines, and updates.
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbol "NGNE" following the anticipated closing of the merger with Neurogene Inc. (the “Merger”), with a new CUSIP number 64135M105. The reverse stock split was effected to ensure the combined company's compliance with the minimum bid price requirement of $4.00 per share for initial listing on the Nasdaq Global Market. The reverse stock split was approved by Neoleukin's stockholders at the Company's special meeting of stockholders held on December 13, 2023, to be effected in the Board's discretion within approved parameters of not less than 1-for-1.5 and not more than 1-for-5. The final reverse stock split ratio was approved by the Board on December 13, 2023. The reverse stock split is expected to reduce the number of shares of the Company's outstanding common stock from approximately 9,398,497 shares to approximately 2,349,624 shares. The number of shares of the Company's authorized common stock was not affected by the reverse stock split, but at the special meeting of stockholders, Neoleukin's stockholders approved an increase in the number of shares of the Company's authorized common stock from 20,000,000 shares to 500,000,000 shares in connection with the anticipated closing of the Merger. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Neoleukin's common stock underlying the Company's outstanding equity awards and pre-funded warrants for common stock, as well as the number of shares of common stock issuable under the Company's equity incentive plan and employee stock purchase plan. There will be no change to the par value per share.
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol “NLTX” with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin's plan to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
San Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its holdings in Neoleukin Therapeutics Inc ( NLTX , Financial), a biopharmaceutical company based in the USA. This article provides an in-depth analysis of the transaction, the profiles of both Redmile Group and Neoleukin Therapeutics, and an evaluation of the latter's financial health and industry position.
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Neoleukin Therapeutics, Inc. (NasdaqCM: NLTX) with Neurogene Inc. Under the terms of the proposed transaction, pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company (subject to certain adjustments) and will also be issued contingent value rights to receive certain pa.
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene
MILWAUKEE , July 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Neurogene. Click here to learn how to join the action https://www.ademilaw.com/case/neoleukin-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) and Neurogene Inc. is fair to Neoleukin shareholders. Pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company. Halper Sadeh encourages Neoleukin shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersade.
Neurogene and Neoleukin Announce Definitive Merger Agreement
NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, and Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene's pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile. Upon completion of the merger, which is subject to approval by Neurogene and Neoleukin stockholders, the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”.
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor Relations Jonathan Drachman - Chief Executive Officer Priti Patel - Chief Medical Officer Sean Smith - Vice President, Finance Conference Call Participants Mary Kate - Bank of America Charles Zhu - Guggenheim Securities Ben Burnett - Stifel Mara Goldstein - Mizuho Securities Operator Good afternoon and thank you for joining us today for the Neoleukin Therapeutics Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows:
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern.
Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.
Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021)
SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the upcoming Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021) taking place November 10-14, 2021, at the Walter E. Washington Convention Center in Washington, D.C.
Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright 23rd Annual Global Life Sciences Conference taking place September 13-15, 2021.
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the Guggenheim Healthcare Talks | 2021 Oncology Days on Friday, March 12, 2021 at 3 p.m. Eastern Time.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX
New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su ch investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Neoleukin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal securities laws. On January 8, 2021, Neoleukin announced that "on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201."...
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for NLTX.